Tom is Interim CEO at Xilis. He has extensive experience as an executive leader, attorney, and board member, guiding strategy for life sciences companies ranging from startups to multi-billion-dollar pharma companies. Tom received his B.S. in Microbiology from the University of California, Santa Barbara, his Ph.D. in Molecular Biochemistry and Biophysics from Illinois Institute of Technology, and his J.D. from Loyola University Chicago School of Law.
Thomas Duke, PhD, JD
Interim Chief Executive Officer
Tom is Interim CEO at Xilis. He has extensive experience as an executive leader, attorney, and board member, guiding strategy for life sciences companies ranging from startups to multi-billion-dollar pharma companies. Tom received his B.S. in Microbiology from the University of California, Santa Barbara, his Ph.D. in Molecular Biochemistry and Biophysics from Illinois Institute of Technology, and his J.D. from Loyola University Chicago School of Law.
Elena Helman, PhD
Vice President of Technology Platform
Elena is Vice President of Technology Platform at Xilis. She has over 10 years of experience in the cancer genomics and diagnostic space, bringing together data analytics and computational tools with a deep knowledge of cancer biology. She has developed diagnostic products across the regulatory landscape, led algorithm design, and biopharma partnerships. Elena was previously Director of Bioinformatics at Guardant Health. She received her PhD in Bioinformatics and Integrative Genomics from the Harvard-MIT Division of Health Sciences and Technology.
Elena Helman, PhD
Vice President of Technology Platform
Elena is Vice President of Technology Platform at Xilis. She has over 10 years of experience in the cancer genomics and diagnostic space, bringing together data analytics and computational tools with a deep knowledge of cancer biology. She has developed diagnostic products across the regulatory landscape, led algorithm design, and biopharma partnerships. Elena was previously Director of Bioinformatics at Guardant Health. She received her PhD in Bioinformatics and Integrative Genomics from the Harvard-MIT Division of Health Sciences and Technology.
Ryan T. Jones, PhD
Vice President of Strategy & Business Development
Ryan is Vice President of Strategy and Business Development. A serial company builder, Ryan has operated in multiple strategy and business development roles at both startups and large Pharma companies. Prior to joining Xilis, Ryan lead strategy and business development at Herophilus, a neuroscience drug discovery startup that built a patient-derived brain organoid drug discovery platform and was acquired by Genentech in 2023. Ryan also coordinated ADC search and evaluation at Stemcentrx following its acquisition by AbbVie, and lead post-acquisition integration of Stemcentrx' partnering activities into AbbVie's corporate strategy office. Ryan has a PhD in neuroscience from the David Geffen School of Medicine at UCLA.
Ryan T. Jones, PhD
Vice President of Strategy & Business Development
Ryan is Vice President of Strategy and Business Development. A serial company builder, Ryan has operated in multiple strategy and business development roles at both startups and large Pharma companies. Prior to joining Xilis, Ryan lead strategy and business development at Herophilus, a neuroscience drug discovery startup that built a patient-derived brain organoid drug discovery platform and was acquired by Genentech in 2023. Ryan also coordinated ADC search and evaluation at Stemcentrx following its acquisition by AbbVie, and lead post-acquisition integration of Stemcentrx' partnering activities into AbbVie's corporate strategy office. Ryan has a PhD in neuroscience from the David Geffen School of Medicine at UCLA.
